TW202210524A - Ｐｃｓｋ９抑制劑及其用於治療膽固醇相關障礙之方法 - Google Patents

Ｐｃｓｋ９抑制劑及其用於治療膽固醇相關障礙之方法 Download PDF

Info

Publication number
TW202210524A
TW202210524A TW110119435A TW110119435A TW202210524A TW 202210524 A TW202210524 A TW 202210524A TW 110119435 A TW110119435 A TW 110119435A TW 110119435 A TW110119435 A TW 110119435A TW 202210524 A TW202210524 A TW 202210524A
Authority
TW
Taiwan
Prior art keywords
ldl
subject
pcsk9
hefh
pediatric
Prior art date
Application number
TW110119435A
Other languages
English (en)
Chinese (zh)
Inventor
安德魯 Ｗ 翰默
伊恩 馬修 畢吉斯
慧 王
安德烈 魯扎
克里斯托弗 庫爾茲
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202210524A publication Critical patent/TW202210524A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW110119435A 2020-05-29 2021-05-28 Ｐｃｓｋ９抑制劑及其用於治療膽固醇相關障礙之方法 TW202210524A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
US63/032,451 2020-05-29

Publications (1)

Publication Number Publication Date
TW202210524A true TW202210524A (zh) 2022-03-16

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110119435A TW202210524A (zh) 2020-05-29 2021-05-28 Ｐｃｓｋ９抑制劑及其用於治療膽固醇相關障礙之方法

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121693519A (zh) 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)

Also Published As

Publication number Publication date
WO2021243002A1 (en) 2021-12-02
IL298375A (en) 2023-01-01
JP2023527542A (ja) 2023-06-29
CA3179316A1 (en) 2021-12-02
AU2021281256A1 (en) 2022-12-22
EP4157887A1 (en) 2023-04-05
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
JOP20220322A1 (ar) 2022-11-27
AR122180A1 (es) 2022-08-24
EP4157887A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US12331122B2 (en) Anti-ASGR-1 monoclonal inhibitory antibodies
TW202210524A (zh) Ｐｃｓｋ９抑制劑及其用於治療膽固醇相關障礙之方法
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
EP4283295A2 (en) Recombinant polyclonal proteins and methods of use thereof
CN107011443B (zh) 用于抑制masp-2依赖的补体活化的组合物
JP2018166516A (ja) 抗ａｎｇｐｔｌ３抗体及びその使用
CN104203980B (zh) 抗‑大‑内皮素‑1(big‑et‑1)抗体及其用途
JP2012500815A (ja) 抗ｃｄ５抗体
JP2018513871A (ja) 片頭痛の治療または予防法
CN103841992A (zh) 治疗或预防胆固醇相关疾病的方法
TW201525004A (zh) 結合前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之人類抗原結合蛋白
JP7558949B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
US20230287112A1 (en) Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
JP7847090B2 (ja) 操作されたｂ型肝炎ウイルス中和抗体およびその使用
WO2022031834A1 (en) Recombinant polyclonal proteins targeting zika and methods of use thereof
US20230265192A1 (en) Anti-ctla-4 binding proteins and methods of use thereof
US20120269814A1 (en) Anti-c mpl antibodies
HK40090853A (zh) Pcsk9抑制剂及其用於治疗胆固醇相关障碍的方法
TW202228768A (zh) 用於治療疼痛之化合物及方法
TW202515895A (zh) 靶向ｂ型肝炎病毒（ｈｂｖ）之重組多株蛋白及其使用方法
HK1242343A1 (en) Compositions for inhibiting masp-2 dependent complement activation